Carillon Tower Advisers, an investment management firm, has released its Q3 2025 Investor Letter “Carillon Eagle Mid Cap Growth Fund.” A copy of the letter can be downloaded here. In the third quarter, stock markets continued their rally, fueled by enthusiasm for AI, limited evidence of inflationary effects of tariffs and expectations of further interest rate cuts from the US Federal Reserve. Mid-cap stocks also maintained their positive gains during the quarter. The Russell Midcap Growth Index (up 2.78%) underperformed the Russell Midcap® Value Index (up 6.16%) during the quarter. The letter further shared the company’s detailed views on the cyclicals, healthcare, information technology, financial and consumer sectors. Additionally, you can look at the fund’s top 5 holdings to determine its top picks for 2025.
In its third quarter 2025 investor letter, the Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company developing therapeutic products for patients with serious and rare diseases. Insmed Incorporated (NASDAQ: INSM)’s one-month return was 25.19% and its shares have gained 173.43% of their value over the past 52 weeks. On November 24, 2025, Insmed Incorporated (NASDAQ: INSM) stock closed at $206.93 per share, with a market cap of $44.133 billion.
The Carillon Eagle Mid Cap Growth Fund stated the following regarding Insmed Incorporated (NASDAQ: INSM) in its Q3 2025 Investor Letter:
“Insmed Incorporated (NASDAQ: INSM) develops therapeutic products for patients with lung diseases. In the second quarter, the company received approval for its Brinsupri product to treat non-cystic bronchiectasis, making it the first treatment available for a condition that affects up to 500,000 people. This milestone, combined with the positive reading of a trial of another company’s treatment for pulmonary fibrosis, boosted the stock’s performance.
Insmed Incorporated (NASDAQ: INSM) is not on our list of the 30 most popular stocks among hedge funds. According to our database, 82 hedge fund portfolios held Insmed Incorporated (NASDAQ: INSM) at the end of the second quarter, up from 64 in the previous quarter. While we recognize the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for a hugely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the reshoring trend, check out our free report on the best AI stock in the short term.
